Conceptual and molecular docking study of newly developed antiepileptic drug cenobamate
1 Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India-110062.
2 Department of Computer Sciences and Engineering, School of Engineering Sciences and Technology, Jamia Hamdard, Hamdard Nagar, New Delhi, India-110062.
Review Article
World Journal of Advanced Research and Reviews, 2023, 17(03), 281–291
Article DOI: 10.30574/wjarr.2023.17.3.0373
Publication history:
Received on 27 January 2023; revised on 06 March 2023; accepted on 08 March 2023
Abstract:
In the past two decades, there has been sudden development in antiepileptic drugs (AEDs) for the adjunctive treatment of epilepsy. CNB is a leading-edge new generation tetrazole-derived carbamate for the treatment of focal-onset epileptic seizures where the mode of action is mediated by blocking voltage-gated sodium channels and interaction with the GABAergic system. The US FDA approved CNB with new hope for superior control over seizure, better safety, and tolerability profile compared to earlier AEDs.
Keywords:
Cenobamate; Tetrazole derivative; Focal-onset seizure; Computational study; Anticonvulsant
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0